<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05041348</url>
  </required_header>
  <id_info>
    <org_study_id>QYFYWZLL26461</org_study_id>
    <nct_id>NCT05041348</nct_id>
  </id_info>
  <brief_title>Metabonomic of Patients With Hepatitis B Cirrhosis Complicated With Sarcopenia.</brief_title>
  <official_title>Affiliated Hospital of Qingdao University</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Affiliated Hospital of Qingdao University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Affiliated Hospital of Qingdao University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Definition of sarcopenia is wasting muscle strength and quality as well as declining physical&#xD;
      performance. The incidence of sarcopenia in liver cirrhosis patients is around 30%-70%, it is&#xD;
      a common complication. The liver-muscle axis suggested that the liver can be connected with&#xD;
      muscle by some medium or metabolism. Some metabolism can influence the synthesis or&#xD;
      decomposition of muscle protein, increase muscle strength and physical function. The study of&#xD;
      the metabonomic differences in patients with cirrhosis complicated with sarcopenia can guide&#xD;
      the nutritional supplement to patients, and reduce the incidence rate of sarcopenia and&#xD;
      improve the prognosis of patients with liver cirrhosis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2021</start_date>
  <completion_date type="Anticipated">August 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>amino acids</measure>
    <time_frame>2021.09.01-2022.08.01</time_frame>
    <description>Amino acids, especially BCCAs, is involved in muscle protein synthesis. So it is important for maintaining and increasing muscle mass . The concentration(Âµmol/L) of amino acids in the blood will be different in the three groups, especially amino acids associated with muscle metabolism.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>myostatin</measure>
    <time_frame>2021.09.01-2022.08.01</time_frame>
    <description>increased myostatin levels contribute to muscle loss. So the concentration(pg/mL) of myostatin predicts to be higher in the sarcopenia patients.</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Sarcopenia</condition>
  <arm_group>
    <arm_group_label>liver cirrhosis with sarcopenia</arm_group_label>
    <description>In order to diagnosis sarcopenia, patients' muscle strength and physical function will be measured. Patients with sarcopenia will show the decrease of muscle strength and physical function.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>liver cirrhosis without sarcopenia</arm_group_label>
    <description>The decrease of muscle strength and physical function will not appear in patients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy group</arm_group_label>
    <description>No related diseases</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>handgrip strength;physical function</intervention_name>
    <description>low muscle strength diagnostic cutoffs of handgrip &lt;28.0 kg for men and &lt;18.0 kg for women.Functional disability studies define slowness as 6-m walk &lt;1.0 m/s.</description>
    <arm_group_label>liver cirrhosis with sarcopenia</arm_group_label>
    <arm_group_label>liver cirrhosis without sarcopenia</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Our research will collect inpatient blood samples of the affiliated hospital of Qingdao&#xD;
        University from August of 2021 to February of 2022. All of the patients are in the&#xD;
        decompensation stage of hepatitis B cirrhosis and divided them into two groups. One group&#xD;
        is named cirrhosis with sarcopenia, the other group is named cirrhosis without sarcopenia.&#xD;
        Each group of patients is about 30.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. the diagnostic criteria for decompensation of liver cirrhosis of chronic viral&#xD;
             hepatitis B formulated according to the Guidelines for Diagnosis and Treatment of&#xD;
             Liver Cirrhosis issued by the Chinese Society of Hepatology in 2019&#xD;
&#xD;
          2. The diagnosis of sarcopenia group conforms to the Asian sarcopenia working group 2019&#xD;
             Consensus Update on the Diagnosis and Treatment of Sarcopenia&#xD;
&#xD;
          3. Patients aged between 18 and 60 years old&#xD;
&#xD;
          4. Patients with no history of drinking or abstinence for more than 1 year&#xD;
&#xD;
          5. Voluntary participants with informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Other types of cirrhosis, such as hepatitis C, alcoholic cirrhosis, non-alcoholic&#xD;
             fatty liver disease, autoimmune liver disease, etc&#xD;
&#xD;
          2. patients with acute, chronic and acute liver failure (course &lt;12 weeks)&#xD;
&#xD;
          3. Other diseases which can lead to the secondary sarcopenia (chronic disease in heart,&#xD;
             lung, kidney, brain, malignant tumor, etc)&#xD;
&#xD;
          4. Neurodegenerative diseases or muscle degenerative diseases&#xD;
&#xD;
          5. Perioperative patients&#xD;
&#xD;
          6. Active exercise (PARS-3 exercise scale is greater than or equal to 20 points as active&#xD;
             exercise&#xD;
&#xD;
          7. Patients with incomplete data&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xuechun Liu</last_name>
    <phone>+8617660935001</phone>
    <email>SeolSoon@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xue Jing</last_name>
    <phone>+8618661807575</phone>
    <email>jingxue@qdu.edu.cn</email>
  </overall_contact_backup>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 15, 2021</study_first_submitted>
  <study_first_submitted_qc>September 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2021</study_first_posted>
  <last_update_submitted>September 2, 2021</last_update_submitted>
  <last_update_submitted_qc>September 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcopenia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

